Share on StockTwits

Equities researchers at Leerink Swann cut their target price on shares of Karyopharm Therapeutics (NASDAQ:KPTI) from $63.00 to $60.00 in a research report issued on Friday. Leerink Swann’s target price indicates a potential upside of 68.92% from the company’s current price.

In other Karyopharm Therapeutics news, major shareholder Marcin Czernik sold 21,570 shares of the stock on the open market in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $36.20, for a total transaction of $780,834.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded up 0.11% during mid-day trading on Friday, hitting $35.52. 171,379 shares of the company’s stock traded hands. Karyopharm Therapeutics has a 52-week low of $15.50 and a 52-week high of $47.98. The stock’s 50-day moving average is $38.15 and its 200-day moving average is $34.05. The company’s market cap is $1.057 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.52. On average, analysts predict that Karyopharm Therapeutics will post $-2.01 earnings per share for the current fiscal year.

Separately, analysts at Oppenheimer downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. One analyst has rated the stock with a hold rating and two have assigned a buy rating to the company. Karyopharm Therapeutics presently has an average rating of “Buy” and a consensus price target of $52.67.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.